Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group

Journal of Clinical Oncology

Volumn 24, Issue 3, 2006, Pages 431-436

  Rajkumar, S Vincent ^a   Blood, Emily ^a   Vesole, David ^a   Fonseca, Rafael ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PAMIDRONIC ACID; PROTEIN; THALIDOMIDE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ADULT; AGED; AGITATION; ANOREXIA; ANXIETY; ARTICLE; BRADYCARDIA; CANCER DIAGNOSIS; CANCER MORTALITY; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DEMOGRAPHY; DESQUAMATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; EDEMA; EMBOLISM; FATIGUE; FEMALE; FOLLOW UP; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INFECTION; INSOMNIA; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; STEM CELL; SYNCOPE; THROMBOSIS; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DRUG POTENTIATION; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33644831033     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.0221     Document Type: Article

References (28)

1. Kyle RA, Rajkumar SV: Plasma cell disorders, in Goldman L, Ausiello D (eds): Cecil Textbook of Medicine (ed 22). Philadelphia, PA, WB Saunders, 2004
2. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
3. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842, 1998
4. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
5. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
6. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86-89, 1990
7. Sirohi B, Powles R: Multiple myeloma. Lancet 363:875-887, 2004
8. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 80:887-890, 1992
9. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
10. Dimopoulos MA, Anagnostopoulos A, Weber D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21:4444-4454, 2003
11. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002
12. Weber DM, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
13. Cavo M, Zamagni E, Tosi P, et al: First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826-831, 2004
14. Kumar S, Witzig TE, Rajkumar SV: Thalidomide: Current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22:2477-2488, 2004
15. Rajkumar SV, Kyle RA: Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol 19:3593-3595, 2001
16. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
17. Kumar S, Gertz MA, Dispenzieri A, et al: Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78:34-39, 2003
18. Richardson P, Schlossman R, Jagannath S, et al: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79:875-882, 2004
19. Weber DM, Rankin K, Gavino M, et al: Thalidomide with dexamethasone for resistant multiple myeloma. Blood 96:167a, 2000 (abstr 719)
20. Anagnostopoulos A, Weber D, Rankin K, et al: Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-771, 2003
21. Palumbo A, Giaccone L, Bertola A, et al: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403, 2001
22. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35-39, 2005
23. Osman K, Comenzo R, Rajkumar SV: Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951-1952, 2001
24. Zangari M, Siegel E, Barlogie B, et al: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 100:1168-1171, 2002
25. Zangari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615, 2001
26. Zangari M, Barlogie B, Thertulien R, et al: Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma 4:32-35, 2003
27. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
28. Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 10.1182/blood-2005-07-2817